Q-omics provides the consensus-scored MTCO3P21 profile across patient tissues and cancer cell-line models. MTCO3P21 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MTCO3P21 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, MTCO3P21 RNA expression shows 7,866 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUSC, KIRC, and HNSC as cancer lineages where MTCO3P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO3P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO3P21 survival associations across molecular data types. MTCO3P21 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO3P21 RNA expression–survival associations across cancer types. High MTCO3P21 expression shows unfavorable associations in LUSC, ACC, CHOL and DLBC, but favorable associations in OV and STAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for MTCO3P21 RNA expression.
This table summarizes MTCO3P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO3P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO3P21 shows lower tumor expression in UCEC and higher tumor expression in KIRC, ESCA, PRAD and LIHC. The KIRC box plot shows higher MTCO3P21 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p < 0.001).
This table shows molecular features associated with MTCO3P21 in patient tissues and cancer cell lines. In patient samples, MTCO3P21 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
